

July 30, 2018

**Allocation System for Haloperidol LA (decanoate) 100 mg/mL 5 mL vials**

Dear Customer,

Effective July 30 until November 10, Sandoz Canada will be temporarily instituting a stock protection and allocation system for Haloperidol LA (decanoate) 100 mg/mL 5 mL vials. While Sandoz Canada is the only supplier of the injectable long acting (LA) form in Canada, other forms of haloperidol as well as alternative therapies are available for patients and they should contact their physician if necessary.

Sandoz Material/Article	Description	DIN	UPC
44005220	Haloperidol LA (decanoate) 100 mg/mL 5 mL vials	02130300	57513029400

This measure is designed to mitigate a back-order risk stemming from a deviation that was detected before the release of the latest batch of the product. Current batches available on the Canadian market are not affected by this issue. A new batch will be produced and released to fully meet our rigorous quality requirements.

Under the allocation system, a percentage of the historical demand, based on the customer's past orders, will be made available and communicated through the NSSR weekly report and [sandozpro.sandoz.ca](http://sandozpro.sandoz.ca). We are doing our best to minimize the impact on our customers and patients. Please do not hesitate to submit an emergency allocation order (EAO) request if this product is needed. We will analyze and answer EAO requests in a timely matter.

We are fully aware of our medicine's importance to patients. This is why we adhere to rigorous international quality and ethical standards, which ensure that we deliver safe and effective medicines. The fact that this issue was detected before the release of the product demonstrates the strength of our internal quality control processes. We have informed Health Canada about this issue and will continue to provide timely and accurate information to healthcare professionals and our customers about any developments.

Should you have any questions, please contact your local Sandoz representative, our Customer Service department at 1-800-361-3062 or our Drug Information and Pharmacovigilance team at 1-800-343-8839, extension 4636.

Thank you for your understanding,

**Martin Arès**

Vice President, Generics & Specialty Products